In the last trading session, 18.85 million AEON Biopharma Inc (AMEX:AEON) shares changed hands as the company’s beta touched 0.05. With the company’s per share price at $0.12 changed hands at $0.01 or 12.12% during last session, the market valuation stood at $9.62M. AEON’s last price was a discount, traded about -14208.33% off its 52-week high of $17.17. The share price had its 52-week low at $0.10, which suggests the last value was 16.67% up since then.

Analysts gave the AEON Biopharma Inc (AEON) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AEON as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. AEON Biopharma Inc’s EPS for the current quarter is expected to be 0.

AEON Biopharma Inc (AMEX:AEON) trade information

Instantly AEON was in green as seen at the end of in last trading. With action -7.46%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -77.72%, with the 5-day performance at -7.46% in the red. However, in the 30-day time frame, AEON Biopharma Inc (AMEX:AEON) is -3.45% down.

AEON Biopharma Inc (AMEX:AEON)’s Major holders

Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 414.9 shares estimated at $49912.0 under it, the former controlled 0.52% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.40% of the shares, roughly 320.9 shares worth around $38604.0.